Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Partners with Cellevate for New Approach to Ovarian Cancer
- Collaboration will use TumorGenesis’ expertise in cancer cell culture growth media in combination with Cellevate’s specialty in emerging field of nanofiber matrixes.
- Cutting-edge technology can help avoid mistakes in $2.6 billion process of bringing new drugs through FDA process.
- Coupling companies’ technology will give researchers ability to grow ovarian cancer tissues in 3D matrix support system with right media for right ovarian cancer cell types
Getting a drug through the complete FDA process, from pre-clinical to approval, is an arduous and expensive task, although there are signs that approval rates are accelerating after years of decline. Companion diagnostics, new approaches and technology are playing important roles in increasing the chances of a drug’s success from the outset—a fact not lost on stakeholders when making investment decisions (https://nnw.fm/HQFAy).
Raising the success rate for experimental cancer drugs starts in the laboratory, where leading-edge technology could be instrumental in providing prescient insights that ultimately result in better clinical outcomes. Looking to give oncology drug developers an upper hand, TumorGenesis, a subsidiary of Predictive Oncology (NASDAQ: POAI), has partnered with Swedish cell culture system company Cellevate AB for the purpose of combining TumorGenesis’ medias with Cellevate’s high engineered matrix materials (https://nnw.fm/xNpt2).
More specifically, the collaboration will involve using TumorGenesis expertise in cancer cell culture growth media in combination with Cellevate’s specialty in the emerging field of nanofiber matrixes. The initial indication for the partners is ovarian cancer, the fifth most deadly type of cancer in women in the U.S. and leading cause of death amongst cancers of the female reproductive system (https://nnw.fm/nsqdI).
The goal is to bring researchers the next generation of tools for hard-to-treat diseases. Armed with new tech, drug developers can aim to avoid early mistakes related to selecting the wrong target based on cancer cell lines. Missteps contribute to the already exorbitant cost of drug development, a figure estimated at $2.6 billion by Tufts Center for the Study of Drug Development (https://nnw.fm/penTX).
Cells in Cellevate’s nanofibers networks are allowed to proliferate and interact with other cells in three dimensions (“3D”), in contrast to the monolayer cultures seen on conventional two-dimensional (“2D”) surfaces. TumorGenesis technology facilitates ex-vivo (outside the body) ovarian cancer cell and tumor growth that mimics that of the patient.
The partnership provides new opportunities for both companies. It further represents an expansion of the Predictive Oncology product portfolio into an area it hadn’t addressed before.
“This combination will give researchers the ability to grow ovarian cancer tissues in a 3D matrix support system with the right media for the right ovarian cancer cell types,” commented Richard Gabriel, SVP of Research & Development at Predictive Oncology. Parent to a family of companies, Predictive Oncology is focused on applying data and artificial intelligence to cancer personalized medicine and drug discovery.
“By combining the strength and expertise of our organizations we believe that we can bring something truly unique and valuable to the market,” commented Cellevate CEO Maximilian Ottosson.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Collaboration will use TumorGenesis’ expertise in cancer cell culture growth media in combination with Cellevate’s specialty in emerging field of nanofiber matrixes.
- Cutting-edge technology can help avoid mistakes in $2.6 billion process of bringing new drugs through FDA process.
- Coupling companies’ technology will give researchers ability to grow ovarian cancer tissues in 3D matrix support system with right media for right ovarian cancer cell types
Getting a drug through the complete FDA process, from pre-clinical to approval, is an arduous and expensive task, although there are signs that approval rates are accelerating after years of decline. Companion diagnostics, new approaches and technology are playing important roles in increasing the chances of a drug’s success from the outset—a fact not lost on stakeholders when making investment decisions (https://nnw.fm/HQFAy).
Raising the success rate for experimental cancer drugs starts in the laboratory, where leading-edge technology could be instrumental in providing prescient insights that ultimately result in better clinical outcomes. Looking to give oncology drug developers an upper hand, TumorGenesis, a subsidiary of Predictive Oncology (NASDAQ: POAI), has partnered with Swedish cell culture system company Cellevate AB for the purpose of combining TumorGenesis’ medias with Cellevate’s high engineered matrix materials (https://nnw.fm/xNpt2).
More specifically, the collaboration will involve using TumorGenesis expertise in cancer cell culture growth media in combination with Cellevate’s specialty in the emerging field of nanofiber matrixes. The initial indication for the partners is ovarian cancer, the fifth most deadly type of cancer in women in the U.S. and leading cause of death amongst cancers of the female reproductive system (https://nnw.fm/nsqdI).
The goal is to bring researchers the next generation of tools for hard-to-treat diseases. Armed with new tech, drug developers can aim to avoid early mistakes related to selecting the wrong target based on cancer cell lines. Missteps contribute to the already exorbitant cost of drug development, a figure estimated at $2.6 billion by Tufts Center for the Study of Drug Development (https://nnw.fm/penTX).
Cells in Cellevate’s nanofibers networks are allowed to proliferate and interact with other cells in three dimensions (“3D”), in contrast to the monolayer cultures seen on conventional two-dimensional (“2D”) surfaces. TumorGenesis technology facilitates ex-vivo (outside the body) ovarian cancer cell and tumor growth that mimics that of the patient.
The partnership provides new opportunities for both companies. It further represents an expansion of the Predictive Oncology product portfolio into an area it hadn’t addressed before.
“This combination will give researchers the ability to grow ovarian cancer tissues in a 3D matrix support system with the right media for the right ovarian cancer cell types,” commented Richard Gabriel, SVP of Research & Development at Predictive Oncology. Parent to a family of companies, Predictive Oncology is focused on applying data and artificial intelligence to cancer personalized medicine and drug discovery.
“By combining the strength and expertise of our organizations we believe that we can bring something truly unique and valuable to the market,” commented Cellevate CEO Maximilian Ottosson.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
